{
  "id": 18221615,
  "title": "Revolution Medicines reiterates $2.1B-$2.2B 2026 GAAP operating expense guidance following RASONQUE launch",
  "url": "https://urgent.news/2026/11/05/revolution-medicines-reiterates-2-1b-2-2b-2026-gaap-operating-expense",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-05T01:35:21.000Z",
  "source": {
    "name": "Seeking Alpha News",
    "slug": "seeking-alpha-news",
    "url": "https://seekingalpha.com/news/4666025-revolution-medicines-reiterates-2_1b-2_2b-2026-gaap-operating-expense-guidance-following?feed_item_type=news"
  },
  "original_language": "en",
  "account": null,
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Revolution Medicines in focus: Rasonque launch on earnings test",
        "url": "https://urgent.news/2026/11/04/revolution-medicines-in-focus-rasonque-launch-on-earnings-test",
        "published": "2026-11-04T18:49:32.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}